Clinical Trial Update: Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) [Phase 1]

View source ↗

Summary

Phase 1 study of vibostolimab alone and in combination with pembrolizumab in advanced solid tumors has completed, with results posted on 2025-10-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-10-14